ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 293

A Systematic Review and Network Meta-Analysis of Long-Term Trials of Pharmacological Treatments in Knee Osteoarthritis

Dario Gregori1, Giampaolo Giacovelli2, Clara Minto1, Beatrice Barbetta2, Francesca Gualtieri2, Danila Azzolina1, Paola Vaghi2 and Lucio C. Rovati2,3, 1Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy, 2Clinical Research Department, Rottapharm Biotech, Monza, Italy, 3University of Milano Bicocca, Milano, Italy

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: meta-analysis and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Osteoarthritis – Clinical Aspects - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthritis (OA) is a chronic and progressive degenerative disease. While management of OA should be directed to long-term control of symptoms and joint structure changes, existing pharmacological agents are mostly studied for their effects on symptoms for short-term periods. This is the first systematic review and meta-analysis investigating the effects of available medications over long-term treatment courses on symptoms and structure in knee OA.

Methods: The Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Scopus and Web of Science were searched for randomized controlled trials (RCTs) of pharmacological interventions in knee OA published until February 29, 2016. Reference lists of retrieved articles were also screened for additional trials. Only RCTs with treatment/follow-up of at least one year were eligible. The primary outcome was knee OA pain change from baseline to the endpoint (≥ 12 months) on a validated scale. Secondary outcomes were changes in physical function and joint structure expressed as radiologic medial tibiofemoral joint space narrowing (JSN). We performed a random-effects network meta-analysis within a Bayesian framework. Imputation methods for mean changes and variability measures were adopted to include papers with incomplete data. Quality of evidence was rated based on the GRADE approach.

Results: Out of 5992 articles for RCTs of drug therapy in knee OA, 38 RCTs involving 18833 patients met the long-term eligibility criteria and included virtually all available pharmacological intervention categories: 27 interventions including placebo for pain (Figure), 13 for physical function and 17 for JSN, with trial duration ranging between 1 and 3 years. There was no evidence of efficacy for most interventions vs placebo, with the exception of prescription glucosamine sulfate that was significant on pain (Figure) and physical function, with a Glass’ Delta Effect Size (ES) of -0.29 [95% credibility interval: -0.49; -0.10] and -0.32 [-0.52, -0.12], respectively, and high quality of evidence rated by GRADE. Glucosamine sulfate, chondroitin sulfate and strontium ranelate were the only interventions able to significantly reduce radiologic JSN (ES 0.42 [0.20; 0.64], 0.20 [0.08; 0.31] and 0.20 [0.06; 0.35], respectively).

Conclusion: This network meta-analysis shows no evidence of efficacy in the long-term management (at least one year) of knee OA for available medications including NSAIDs, corticosteroids, acetaminophen, putative disease-modifiers, most bone acting agents or Slow Acting Drugs in OA. The only exception is prescription glucosamine sulfate, that is consistently effective on symptoms and joint structure changes, while chondroitin sulfate and strontium ranelate are effective only on structure. Additional long-term RCTs of available and new medications are needed in OA.


Disclosure: D. Gregori, Rottapharm Biotech, 5; G. Giacovelli, Rottapharm Biotech, 3; C. Minto, Rottapharm Biotech, 5; B. Barbetta, Rottapharm Biotech, 3; F. Gualtieri, Rottapharm Biotech, 3; D. Azzolina, Rottapharm Biotech, 5; P. Vaghi, Rottapharm Biotech, 3; L. C. Rovati, Rottapharm Biotech, 3.

To cite this abstract in AMA style:

Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, Azzolina D, Vaghi P, Rovati LC. A Systematic Review and Network Meta-Analysis of Long-Term Trials of Pharmacological Treatments in Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-systematic-review-and-network-meta-analysis-of-long-term-trials-of-pharmacological-treatments-in-knee-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-systematic-review-and-network-meta-analysis-of-long-term-trials-of-pharmacological-treatments-in-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology